Skip to main content

01.12.2010 | Research | Ausgabe 1/2010 Open Access

Journal of Inflammation 1/2010

Pharmacokinetics of Linezolid and Ertapenem in experimental parapneumonic pleural effusion

Journal of Inflammation > Ausgabe 1/2010
Maria Saroglou, Stavros Tryfon, Georgios Ismailos, Ioannis Liapakis, Manolis Tzatzarakis, Aristidis Tsatsakis, Apostolos Papalois, Demosthenes Bouros
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1476-9255-7-22) contains supplementary material, which is available to authorized users.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions and agreement

MS carried out the experimental protocol and collected all the data. ST and GI contributed in the design of the protocol, performed the statistical analysis, were involved in the drafting of the manuscript and carried out the revisions of the final version. MT and AT participated in the design of the study, carried out the analytical procedures and were involved in the drafting of the methodology of the manuscript. IL and AP participated in the design and the validation of the empyemic rabbit model. DB designed the experimental protocol and gave the final approval for the submission of this manuscript.
All authors read and approved the final manuscript.
This study was supported by a grant from Experimental Research Center ELPEN A. E. Farma, Athens, Greece.



To determine the extent of linezolid and ertapenem penetration into the empyemic fluid using a rabbit model of empyema.


An empyema was created via the intrapleural injection of Escherichia coli bacteria (ATCC 35218) into the pleural space of New Zealand white rabbits. After an empyema was verified by thoracocentesis, 24 hours post inoculation, linezolid (10 mg/kg) and ertapenem (60 mg/kg) were administered intravenously into 10 and 8 infected empyemic rabbits, respectively. Antibiotic levels were determined in samples of pleural fluid and blood serum, collected serially at 1, 2, 4, 6 and 8 hours, after administration each of the two antibiotics.


Linezolid as well as ertapenem penetrate well into the empyemic pleural fluid, exhibiting a slower onset and decline compared to the corresponding blood serum levels. Equilibration between blood serum and pleural fluid compartments seems to occur at 1.5 hours for both linezolid and ertapenem, with peak pleural fluid levels (Cmaxpf of 2.02 ± 0.73 «mu»g/ml and Cmaxpf of 3.74 ± 1.39 «mu»g/ml, correspondingly) occurring 2 hours post antibiotics administration and decreasing very slowly thereafter. The serum concentrations for both antibiotics were significantly lower from the corresponding pleural fluid ones during the 8 hours collecting data, with the exception of samples collected at the 1st hour (Cmaxserum of 2.1 ± 1.2 «mu»g/ml for linezolid and Cmaxserum of 6.26 ± 2.98 «mu»g/ml for ertapenem).


Pleural fluid levels of both antibiotics are inhibitory for common specified pathogens causing empyema.
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2010

Journal of Inflammation 1/2010 Zur Ausgabe

Neu im Fachgebiet Innere Medizin

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Innere Medizin und bleiben Sie gut informiert – ganz bequem per eMail.

© Springer Medizin